Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?

被引：6
|
作者：
Munir, Kashif M. [1 ]
Davis, Stephen N. [2 ]
机构：
[1] Univ Maryland, Sch Med, Ctr Diabet & Endocrinol, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, 22 South Greene St, Baltimore, MD 21201 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2018年 / 19卷 / 08期
关键词：
GLP-1 receptor agonist; SGLT2; inhibitor; type; 2; diabetes; cardiovascular outcomes; GLUCOSE-LOWERING DRUGS; CARDIOVASCULAR OUTCOMES; CVD-REAL; MORTALITY; EMPAGLIFLOZIN; LIRAGLUTIDE;
D O I：
10.1080/14656566.2018.1475559
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：773 / 777
页数：5
相关论文
共 50 条
  • [41] SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: BMJ Rapid Recommendation
    Arnold, Michael J.
    Buelt, Andrew
    AMERICAN FAMILY PHYSICIAN, 2022, 105 (06) : 675 - 677
  • [42] SGLT2 inhibitor and GLP-1 analogue combination therapy in Type 2 diabetes
    Bashir, J.
    Stephens, J.
    Anderson, R.
    Hayes, J.
    Elamin, O.
    Lloyd, A.
    DIABETIC MEDICINE, 2016, 33 : 165 - 166
  • [43] Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
    Edwards, Khary
    Li, Xilong
    Lingvay, Ildiko
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (04): : 920 - 930
  • [44] Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
    Castellana, Marco
    Cignarelli, Angelo
    Brescia, Francesco
    Perrini, Sebastio
    Natalicchio, Annalisa
    Laviola, Luigi
    Giorgino, Francesco
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [45] Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
    Marco Castellana
    Angelo Cignarelli
    Francesco Brescia
    Sebastio Perrini
    Annalisa Natalicchio
    Luigi Laviola
    Francesco Giorgino
    Scientific Reports, 9
  • [46] Comparative effectiveness of GLP-1 receptor agonists versus SGLT2 inhibitors in patients with type 2 diabetes and moderate chronic kidney disease
    Rossing, P.
    Fioretto, P.
    Clark, A.
    Jensen, A. B.
    Nazal, N. Belmar
    Tuttle, K. R.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S356 - S357
  • [47] Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology, and Primary Care Visits
    Dixon, Dave L.
    Salgado, Teresa M.
    Robinson, Amanda
    Carbone, Salvatore
    Wagner, Tyler D.
    Hyder, Haroon
    Kirschner, Bryan
    Musselman, Kerri T.
    Buffington, Tonya M.
    Sabo, Roy T.
    MAYO CLINIC PROCEEDINGS, 2025, 100 (04) : 647 - 656
  • [48] Prescription Patterns for GLP-1 Receptor Agonists and SGLT2 Inhibitors by Physicians' Years in Practice
    Inoue, Kosuke
    Kazi, Dhruv S.
    Vaduganathan, Muthiah
    Wadhera, Rishi K.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2025,
  • [49] SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum
    Preston, Frank G.
    Anson, Matthew
    Riley, David R.
    Ibarburu, Gema H.
    Henney, Alexander
    Lip, Gregory Y. H.
    Cuthbertson, Daniel J.
    Alam, Uazman
    Zhao, Sizheng S.
    CLINICAL THERAPEUTICS, 2024, 46 (11) : 835 - 840
  • [50] GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?
    Santulli, Gaetano
    Mone, Pasquale
    Varzideh, Fahimeh
    FUTURE CARDIOLOGY, 2025, 21 (01) : 5 - 8
12345